However, the analyses of the Seeger dataset with 102 patients with non-MYCN amplified neuroblastoma using the R2 platform showed unfavorable prognosis in patients with low PRMT1 expression levels (Fig. 1A). This evidence concerns the gene MYCN and neuroblastoma.